PDF(Pubmed)
Abstract：
UNASSIGNED: Epilepsy is a persistent tendency to experience epileptic seizures and can lead to various neurobiological disorders, with an elevated risk of premature mortality. This study evaluates the efficacy of brivaracetam adjuvant therapy in patients with epilepsy.
UNASSIGNED: A prospective observational multicentre study that was conducted in Pakistan from March to September 2022, by using a non-probability convenience sampling technique. The population consisted of 543 individuals with a diagnosis of epilepsy for whom adjunctive brivaracetam (Brivera; manufactured by Helix Pharma Pvt Ltd., Sindh, Pakistan) was recommended by the treating physician. The research sample was drawn from various private neurology clinics of Karachi, Lahore, Rawalpindi, Islamabad and Peshawar. Data originating from routine patient visits, and assessments at three study time points, were recorded in the study case report form.
UNASSIGNED: Across 18 clinical sites, 543 individuals participated, with a mean age of 32.9 years. The most prescribed dosages were 50 mg BD, followed by 100 mg BD. Notably, brivaracetam combined with divalproex sodium was the most prevalent treatment, followed by brivaracetam with levetiracetam. At both the 14th and 90th day assessments, a significant reduction in seizure frequency was observed, with 63.1% of individuals showing a favourable response by day 90. Treatment-naive individuals exhibited higher rates of seizure freedom and response compared with treatment-resistant individuals.
UNASSIGNED: The study demonstrates the effectiveness of brivaracetam combination therapy in epilepsy management, with notable reductions in seizure frequency and favourable clinical responses observed, particularly in treatment-naive individuals.
UNASSIGNED: A prospective observational multicentre study that was conducted in Pakistan from March to September 2022, by using a non-probability convenience sampling technique. The population consisted of 543 individuals with a diagnosis of epilepsy for whom adjunctive brivaracetam (Brivera; manufactured by Helix Pharma Pvt Ltd., Sindh, Pakistan) was recommended by the treating physician. The research sample was drawn from various private neurology clinics of Karachi, Lahore, Rawalpindi, Islamabad and Peshawar. Data originating from routine patient visits, and assessments at three study time points, were recorded in the study case report form.
UNASSIGNED: Across 18 clinical sites, 543 individuals participated, with a mean age of 32.9 years. The most prescribed dosages were 50 mg BD, followed by 100 mg BD. Notably, brivaracetam combined with divalproex sodium was the most prevalent treatment, followed by brivaracetam with levetiracetam. At both the 14th and 90th day assessments, a significant reduction in seizure frequency was observed, with 63.1% of individuals showing a favourable response by day 90. Treatment-naive individuals exhibited higher rates of seizure freedom and response compared with treatment-resistant individuals.
UNASSIGNED: The study demonstrates the effectiveness of brivaracetam combination therapy in epilepsy management, with notable reductions in seizure frequency and favourable clinical responses observed, particularly in treatment-naive individuals.
摘要：
癫痫是癫痫发作的持续倾向，可导致各种神经生物学疾病，过早死亡的风险升高。本研究评估布立西坦辅助治疗癫痫患者的疗效。
■一项前瞻性观察性多中心研究，于2022年3月至9月在巴基斯坦进行，采用非概率便利抽样技术。该人群由543名诊断为癫痫的人组成，其中有辅助brivacetam（Brivera；由HelixPharmaPvtLtd.制造，信德省,巴基斯坦）是主治医生推荐的。研究样本来自卡拉奇的各个私人神经科诊所，拉合尔,拉瓦尔品第,伊斯兰堡和白沙瓦。来自常规患者就诊的数据，在三个研究时间点进行评估，记录在研究案例报告表中。
■在18个临床地点，543人参加，平均年龄32.9岁.最常用的剂量是50毫克BD，其次是100mgBD。值得注意的是,布立西坦联合双丙戊酸钠是最普遍的治疗方法，其次是brivaracetam与左乙拉西坦。在第14天和第90天的评估中，观察到癫痫发作频率显着降低，到第90天，63.1%的人表现出良好的反应。与治疗抵抗的个体相比，未接受治疗的个体表现出更高的癫痫发作自由和反应率。
■该研究证明了布立西坦联合治疗在癫痫治疗中的有效性，癫痫发作频率显着降低，临床反应良好，特别是在治疗幼稚的个体中。
■一项前瞻性观察性多中心研究，于2022年3月至9月在巴基斯坦进行，采用非概率便利抽样技术。该人群由543名诊断为癫痫的人组成，其中有辅助brivacetam（Brivera；由HelixPharmaPvtLtd.制造，信德省,巴基斯坦）是主治医生推荐的。研究样本来自卡拉奇的各个私人神经科诊所，拉合尔,拉瓦尔品第,伊斯兰堡和白沙瓦。来自常规患者就诊的数据，在三个研究时间点进行评估，记录在研究案例报告表中。
■在18个临床地点，543人参加，平均年龄32.9岁.最常用的剂量是50毫克BD，其次是100mgBD。值得注意的是,布立西坦联合双丙戊酸钠是最普遍的治疗方法，其次是brivaracetam与左乙拉西坦。在第14天和第90天的评估中，观察到癫痫发作频率显着降低，到第90天，63.1%的人表现出良好的反应。与治疗抵抗的个体相比，未接受治疗的个体表现出更高的癫痫发作自由和反应率。
■该研究证明了布立西坦联合治疗在癫痫治疗中的有效性，癫痫发作频率显着降低，临床反应良好，特别是在治疗幼稚的个体中。
